GPR34 Antibody (Center) Blocking peptide
Synthetic peptide
- SPECIFICATION
- CITATIONS
- PROTOCOLS
- BACKGROUND
Primary Accession | Q9UPC5 |
---|---|
Clone Names | 100405156 |
Gene ID | 2857 |
---|---|
Other Names | Probable G-protein coupled receptor 34, GPR34 |
Format | Peptides are lyophilized in a solid powder format. Peptides can be reconstituted in solution using the appropriate buffer as needed. |
Storage | Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C. |
Precautions | This product is for research use only. Not for use in diagnostic or therapeutic procedures. |
Name | GPR34 |
---|---|
Function | G-protein-coupled receptor of lysophosphatidylserine (LysoPS) that plays different roles in immune response (PubMed:16460680). Acts a damage-sensing receptor that triggers tissue repair upon recognition of dying neutrophils (By similarity). Mechanistically, apoptotic neutrophils release lysophosphatydilserine that are recognized by type 3 innate lymphoid cells (ILC3s) via GPR34, which activates downstream PI3K-AKT and RAS-ERK signaling pathways leading to STAT3 activation and IL-22 production (By similarity). Plays an important role in microglial function, controlling morphology and phagocytosis (By similarity). |
Cellular Location | Cell membrane; Multi-pass membrane protein |
Tissue Location | Broadly expressed. Highly expressed on mast cells (PubMed:16460680). |
Thousands of laboratories across the world have published research that depended on the performance of antibodies from Abcepta to advance their research. Check out links to articles that cite our products in major peer-reviewed journals, organized by research category.
info@abcepta.com, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
Background
G protein-coupled receptors (GPCRs), such as GPR34, areintegral membrane proteins containing 7 putative transmembranedomains (TMs). These proteins mediate signals to the interior ofthe cell via activation of heterotrimeric G proteins that in turnactivate various effector proteins, ultimately resulting in aphysiologic response.
References
Engemaier, E., et al. Genomics 87(2):254-264(2006)Oh, J.H., et al. Mamm. Genome 16(12):942-954(2005)Jacobi, F.K., et al. Hum. Genet. 107(1):89-91(2000)Schoneberg, T., et al. Biochim. Biophys. Acta 1446 (1-2), 57-70 (1999) :Marchese, A., et al. Genomics 56(1):12-21(1999)
If you have used an Abcepta product and would like to share how it has performed, please click on the "Submit Review" button and provide the requested information. Our staff will examine and post your review and contact you if needed.
If you have any additional inquiries please email technical services at tech@abcepta.com.